NEW YORK, Jan 31 - PPD Discovery said Wednesday it would license Affymetrix' GeneChip DNA microarrays as well as its array instrumentation and analysis software.
The company will use the Affymetrix products in its functional genomics-based drug target validation efforts. PPD Discovery, a subsidiary of drug discovery and development services company PPD, uses its genomics platform to isolate gene inhibitors for cells, in order to identify novel therapeutic targets and gain insights on genome function.
" Affymetrix' technology adds a new dimension to our functional genomics program," Tanya Holzmayer, vice president of genomics at PPD Discovery, said in a statement. " We have evaluated a variety of expression profiling technologies and believe that Affymetrix' GeneChip technology will considerably expedite our process of target validation."
The companies did not disclose the financial terms of the agreement.
Some of Affymetrix’s other GeneChip Platform and service access customers have included Astra, Bristol-Myers Squibb, DNAX, Eli Lilly, Human Genome Sciences, Genecor, Glaxo Wellcome, Merck, Millennium, Novartis, Pharmacia & Upjohn, Pioneer, Research Genetics, Rosetta, Sanofi Recherche, Schering, and Tularik.